AI Article Synopsis
- The review highlights the use of dual pathway inhibition to improve treatment outcomes for patients with coronary or peripheral artery disease.
- It combines low-dose rivaroxaban (2.5 mg twice daily) to decrease thrombin generation and aspirin (100 mg once daily) to lower platelet activation.
- This combination therapy has been approved for secondary prevention in patients already diagnosed with these vascular conditions.
Article Abstract
This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet activation. Such therapy has been licensed for secondary prevention in patients with coronary or peripheral artery disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2019.09.033 | DOI Listing |
Publication Analysis
Top Keywords
dual pathway
8
pathway inhibition
8
rivaroxaban aspirin
4
aspirin cardiovascular
4
cardiovascular protection
4
protection rationale
4
rationale vascular
4
vascular dose
4
dose dual
4
inhibition review
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!